NCT04525417

Brief Summary

The study objectives were to assess 1/the immune status of healthcare professionals with suggestive symptomatology of Covid-19 infection and 2/the sensitivity and specificity of AAZ rapid test by comparing it with a serological ELISA test. An open-label, monocentric, prospective, non-randomized study, is conducted, including 50 hospital healthcare professionals and 50 private health professionals. Knowledge of serostatus will achieve the implementation of a strategy of management of patients according to specific immunity of health professionals

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 25, 2020

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 21, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 25, 2020

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 25, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 25, 2020

Completed
Last Updated

February 3, 2021

Status Verified

August 1, 2020

Enrollment Period

5 months

First QC Date

August 21, 2020

Last Update Submit

February 2, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • To assess the predictive value of Covid-19 rapid test

    Comparative study with Elisa Test

    One week

  • Compare the results of rapid tests on serum and capillary samples

    Performance evaluation of rapid tests according to the samples used

    one week

Secondary Outcomes (2)

  • A posteriori diagnosis of a covid-19 recent infection with suggestive symptomatology

    one week

  • Analysis of factors associated with negativity of PCR test on oropharyngeal swabs and positive serology

    One week

Study Arms (2)

hospital healthcare workers

OTHER

Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test

Diagnostic Test: AAZ Covid-19 rapid test

private health professionals

OTHER

Clinical examination; Veinous blood sampling for serological testing; capillary drawing to perform a rapid Covid-19 test

Diagnostic Test: AAZ Covid-19 rapid test

Interventions

To assess the immune status

Also known as: ELISA test
hospital healthcare workersprivate health professionals

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthcare professionals with symptoms suggestive of Covid-19 infection

You may not qualify if:

  • any other subject
  • pregnant women
  • protected adult

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bichat University Hospital

Paris, F-75018, France

Location

Study Officials

  • Elisabeth Bouvet, MD

    Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: Monocentric, open-label, prospective, non-randomized study
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 21, 2020

First Posted

August 25, 2020

Study Start

April 25, 2020

Primary Completion

September 25, 2020

Study Completion

October 25, 2020

Last Updated

February 3, 2021

Record last verified: 2020-08

Data Sharing

IPD Sharing
Will not share

Locations